ADU-S100 + ipilimumab
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Solid Tumors or Lymphomas
Conditions
Advanced/Metastatic Solid Tumors or Lymphomas
Trial Timeline
Apr 28, 2016 → Aug 6, 2020
NCT ID
NCT02675439About ADU-S100 + ipilimumab
ADU-S100 + ipilimumab is a phase 1 stage product being developed by Novartis for Advanced/Metastatic Solid Tumors or Lymphomas. The current trial status is terminated. This product is registered under clinical trial identifier NCT02675439. Target conditions include Advanced/Metastatic Solid Tumors or Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02675439 | Phase 1 | Terminated |
Competing Products
20 competing products in Advanced/Metastatic Solid Tumors or Lymphomas